Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

Novartis Ag

Ortho-Clinical Diagnostics, Inc

Grifols Worldwide Operations Limited

Norvartis Ag

Doris Guenzi Coit

Angelica Medina-Selby

Michael Houghton

David Y Chien

John Andrew Hall

Stephen David Harrison

Carlos George-Nascimento

Maria Calderon-Cacia

Ziyang Zhong

Steve H Nguyen

Laura Tandeske

Eric Y Fang

Phillip M Arcangel

Michael Vajdy

Colin McCoin

Mark J Selby

Philip R Dormitzer

Ethan Settembre

Jian Zheng

Alexander Gyenes

Toshiya Fujihara

Sansan Lin

Phillip Arcangel

Qui-Lim Choo

Stephen R Coates

Sergio Pichuantes

Yiu-Lian Fong

Charles A Harrington

Yin-Ling Lin

William Andrews

Stephen Coates

Susan Hilt

Celine Hu

Carlos George-Nasciemento

Colin Mccoin

Charles Harrington

David Ying Chien

Lin Sansan

Modified hepatitis C virus polypeptides are described. The polypeptides include the HCV NS4a domain and modified NS3 domain. The polypeptides retain conformational epitopes. HCV immunoassays including the polypeptides are also described.

HCV NS4a/modified NS3 polypeptides and uses thereof

The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.

Norovirus derived immunogenic compositions and methods

HCV NS4A/modified NS3 polypeptides and uses thereof

The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.

Method for generating a parvovirus B19 virus-like particle

Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus.

Norovirus and Sapovirus antigens

Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.

Immunogenic reagents from west nile virus

The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.

HCV fusion polypeptides

Norovirus and sapovirus antigens

Methods for producing norovirus VLPS

Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.

HCV non-structural polypeptide

Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.

HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&#x3b1; and GSK3&#x3b2; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

GSK3 polypeptides

Growing community of inventors

Petaluma, CA, United States of America

Doris Guenzi Coit